Synthesis and antibacterial potential of novel thymol derivatives against methicillin-resistant Staphylococcus aureus and P. aeruginosa pathogenic bacteria

• Published in: Frontiers in chemistry Vol. 12; p. 1482852
• Main Authors: Shahi, Ashutosh, Manhas, Rakshit, Bhattacharya, Srija, Rathore, Arti, Kumar, Puneet, Samanta, Jayanta, Sharma, Manish Kumar, Mahapa, Avisek, Gupta, Prasoon, Anal, Jasha Momo H
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16.10.2024
• Subjects: antibacterial; antibiotic resistance; Chemistry; drug discovery; synergistic effect; thymol derivatives; antibacterial; drug discovery; antibiotic resistance; synergistic effect; thymol derivatives
• ISSN: 2296-2646; 2296-2646
• DOI: 10.3389/fchem.2024.1482852

The increasing threat of antibiotic resistance has created an urgent need for new antibacterial agents, particularly plant-based natural compounds and their derivatives. Thymol, a natural monoterpenoid phenolic compound derived from , is known for its aromatic and therapeutic properties, including antibacterial activity. This study focuses on synthesizing dihydropyrimidinone and dihydropyridine derivatives of thymol and exploring their antibacterial properties. The synthesized compounds were tested for their antibacterial potential against pathogenic microorganisms, specifically (Gram-negative) and methicillin-resistant (MRSA) (Gram-positive). Among the synthesized derivatives, compound 3i (ethyl 4-(4-hydroxy-5-isopropyl-2-methylphenyl)-2-imino-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate) exhibited the most promising antibacterial activity, with minimum inhibitory concentration (MIC) values of 12.5 µM against and 50.0 µM against MRSA. Additionally, compound 3i demonstrated a synergistic effect when combined with vancomycin, enhancing its antibacterial efficacy. The optimum fractional inhibitory concentration index (FICI) observed was 0.10 and 0.5 for MRSA and , respectively, in combination with vancomycin. analysis of the physiochemical properties of 3i indicated compliance with all drug-likeness rules. Furthermore, molecular docking studies revealed that compound 3i has a stronger binding affinity to the target protein than thymol, providing valuable insights into its potential mechanism of action.